TEVA logo

Teva Pharmaceutical Industries Limited (TEVA)

$42.57

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TEVA

Market cap

$49.67B

EPS

0.44

P/E ratio

67.3

Price to sales

2.77

Dividend yield

--

Beta

0.852297

Price on TEVA

Previous close

$44.50

Today's open

$44.30

Day's range

$42.52 - $44.57

52 week range

$26 - $44.57

Profile about TEVA

CEO

Richard D. Francis

Employees

33950

Headquarters

Parsippany, NJ

Exchange

New York Stock Exchange

Shares outstanding

1.17B

Issue type

Common Stock

TEVA industries and sectors

Healthcare

Pharmaceuticals

News on TEVA

David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes

DME Capital Management LP, founded and led by well-known investor David Einhorn , unveiled its newest third-quarter stock positions and fund changes on Monday. Here are the latest moves.

news source

Benzinga • 12 hours ago

news preview

FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use.

news source

Benzinga • Nov 16, 2026

news preview

Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030

Teva Pharmaceutical Industries NYSE: TEVA outlined plans to grow its innovative medicines business and advance a pipeline spanning neuroscience, immunology and cancer treatments at its first R&D Day.

news source

MarketBeat • Nov 11, 2026

news preview

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.

news source

GlobeNewsWire • Nov 11, 2026

news preview

Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

Teva improved margins significantly. The pharmaceutical company has paid down net debt.

news source

The Motley Fool • Nov 6, 2026

news preview

What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call

Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by lower generic-drug sales, particularly generic REVLIMID.

news source

MarketBeat • Nov 4, 2026

news preview

Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up

Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Teva Pharmaceutical Q3 profit gain beats estimates

Israeli drugmaker Teva Pharmaceutical Industries, reported on Tuesday ​a higher-than-expected rise in third-quarter ‌profit, helped by strong sales of a trio of its own ​drugs to offset declines in ​copycat medicines.

news source

Reuters • Nov 3, 2026

news preview

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

Teva Pharmaceutical Industries expects to grow in ​2027 despite the US ‌inflation reduction act that will cap prices for its top ​branded drug Austedo to ​treat Huntington's Disease and Tardive ⁠Dyskinesia, CEO Richard Francis ​said on Tuesday.

news source

Reuters • Nov 3, 2026

news preview

Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat

Teva stock advanced early Tuesday on better-than-expected third-quarter metrics and a raised outlook for 2026.

news source

Investors Business Daily • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Teva Pharmaceutical Industries Limited

Open an M1 investment account to buy and sell Teva Pharmaceutical Industries Limited commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TEVA on M1